Market Overview

UPDATE: Bank Of America Downgrades Seattle Genetics, Inc. On Frontline Expectations

Share:

In a report published Tuesday, Bank of America analyst Steve Byrne downgraded the rating on Seattle Genetics, Inc. (NASDAQ: SGEN) from Neutral to Underperform, and lowered the price target from $40.00 to $34.00.

In the report, Bank of America noted, “Following PTCL data from ESMO and post-transplant Hodgkin Lymphoma (HL) AETHERA data, we are lowering our rating to Underperform (from Neutral) and our DCF-derived PO to $34 (from $40). While consolidation in post-autologous stem cell transplantation (ASCT) HL with Adcetris had a 75% progression free survival (PFS) advantage vs. placebo, the interim overall survival (OS) advantage was not significant. While this could reflect limited statistical power with few events, it appears to be partly due to use of Adcetris post-progression in the placebo arm. We raised the probability of approval in this setting to 70% (from 60%), but we slowed the ramp pending OS data in 2016. In our view, the lack of survival advantage could reinforce Adcetris' role as salvage therapy and less as a frontline option. Our model revisions were primarily in the frontline settings (see below).”

Seattle Genetics, Inc. closed on Monday at $38.39.

Latest Ratings for SGEN

DateFirmActionFromTo
Oct 2020Morgan StanleyMaintainsEqual-Weight
Oct 2020SVB LeerinkMaintainsOutperform
Oct 2020B of A SecuritiesMaintainsNeutral

View More Analyst Ratings for SGEN
View the Latest Analyst Ratings

 

Related Articles (SGEN)

View Comments and Join the Discussion!

Posted-In: Bank of America Steve ByrneAnalyst Color Downgrades Analyst Ratings

Latest Ratings

StockFirmActionPT
HYMCBMO CapitalInitiates Coverage On
DEMorgan StanleyMaintains335.0
SBNYRaymond JamesMaintains138.0
CORTHC Wainwright & Co.Maintains32.0
CYBBFCitigroupDowngrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com